Latest News
First Patient Dosed in Phase I trial studying TILT-123 and anti-PD-L1
TILT Biotherapeutics Announces Close of Financing Round to Advance to Phase II Oncology Immunotherapy Trials
Upcoming Events
Please contact our business development team to meet us at the following events: